Abcellera Biologics is trading at $12.39, up +4.34%, as U.S. markets rebound, with the S&P 500, Nasdaq and Dow all sharply higher.
- The company is scheduled to report Q3 2026 results after the November 9 market close, keeping investors focused on clinical updates and ABCL635.
- At 10:28 a.m. EST, the report was still upcoming, so there were no results to explain the move yet.